Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference

8/21/24 7:00:00 AM ET

Industrial Specialties

Health Care

Get the next $EW alert in real time by email

Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024.

Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day.

About Edwards Lifesciences

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, X and YouTube.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240821162139/en/

Get the next $EW alert in real time by email

Date	Price Target	Rating	Analyst
10/11/2024	$70.00	Equal-Weight	Morgan Stanley
9/18/2024	$85.00 → $70.00	Buy → Hold	Jefferies
7/31/2024		Neutral → Outperform	Daiwa Securities
7/29/2024		Underperform → Peer Perform	Wolfe Research
7/25/2024	$100.00 → $70.00	Buy → Hold	TD Cowen
7/25/2024	$105.00 → $75.00	Buy → Neutral	BofA Securities
7/25/2024	$102.00 → $70.00	Outperform → Neutral	Robert W. Baird
7/25/2024	$105.00 → $72.00	Overweight → Neutral	JP Morgan

Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $EW

$EW Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley resumed coverage on Edwards Lifesciences with a new price target

Edwards Lifesciences downgraded by Jefferies with a new price target

Edwards Lifesciences upgraded by Daiwa Securities

$EW Press Releases

Fastest customizable press release news feed in the world

Data Presented at TCT Reinforce Edwards Lifesciences' Commitment to Structural Heart Innovation

TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

$EW Market Insights

Live Market Insights

This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Stifel Maintains Hold on Edwards Lifesciences, Lowers Price Target to $70

Oppenheimer Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $90

$EW SEC Filings

SEC Form 10-Q filed by Edwards Lifesciences Corporation

Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Edwards Lifesciences Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$EW Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Global President TAVR & Surg Wood Larry L sold $1,647,862 worth of shares (25,000 units at $65.91), decreasing direct ownership by 11% to 198,526 units (SEC Form 4)

CVP,Strategy/Corp Development Bobo Donald E Jr exercised 5,000 shares at a strike of $45.28 and sold $347,534 worth of shares (5,000 units at $69.51) (SEC Form 4)

GM & SVP, Surgical Markowitz Wayne covered exercise/tax liability with 648 shares, decreasing direct ownership by 6% to 10,033 units (SEC Form 4)

$EW Financials

Live finance-specific insights

Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences to Host Earnings Conference Call on October 24, 2024

Edwards Lifesciences Reports Second Quarter Results

$EW Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

$EW Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

$EW Leadership Updates

Live Leadership Updates

EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

Edwards Announces Updates From Annual Meeting

Recent Analyst Ratings for
$EW

$EW
Analyst Ratings

$EW
Press Releases

$EW
Market Insights

$EW
SEC Filings

$EW
Insider Trading

$EW
Financials

$EW
Large Ownership Changes

$EW
Insider Purchases

$EW
Leadership Updates